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a b s t r a c t
Progression of prion diseases is driven by the accumulation of prions in the brain. Ablation of microglia or
deletion of the eat-me-signal, milk-fat globule epidermal growth factor VIII (Mfge8), accelerates prion
pathogenesis, suggesting that microglia defend the brain by phagocytosing prions. Similar to Mfge8,
developmental endothelial locuse1 (Del-1) is a secreted protein that acts as an opsonin bridging phago-
cytes and apoptotic cells to facilitate phagocytosis. We therefore asked whether Del-1 might play a role in
controlling prionpathogenesis.We assessed the anti-inﬂammatoryand phagocytosis-promoting functions
of Del-1 in prion disease and determined whether Del-1 complements Mfge8 in prion clearance in mice
with a C57BL/6J genetic background. We found that Del-1 deﬁciency did not change prion disease pro-
gression or lesionpatterns. In addition, prion clearance and scrapie prionproteindepositionwereunaltered
in Del-1edeﬁcient mice. In addition, prion-induced neuroinﬂammation was not affected by Del-1 deﬁ-
ciency. We conclude that Del-1 is not a major determinant of prion pathogenesis in this context.
 2019 Elsevier Inc. All rights reserved.
1. Introduction
Prion diseases are lethal neurodegenerative disorders that affect
both animals and humans (Aguzzi et al., 2013b). Prion diseases are
characterized by deposition of the scrapie prion protein (PrPSc), a
misfolded form of the cellular prion protein, in the central nervous
system (CNS) (Aguzzi and Zhu, 2012). The accumulation of PrPSc
within the CNS is accompanied by astrogliosis, microglial activa-
tion, and neuronal loss.
Microglia are the main innate immune cells in the CNS, exerting a
defensive role against prions (Aguzzi andZhu, 2017; Falsiget al., 2008;
Zhu et al., 2016). However, the molecular mechanisms underlying
prion clearance by microglia are not entirely clear. We have reported
enhanced prion pathogenesis in mice lacking the astrocytes-borne
opsonin protein, milk-fat globule epidermal growth factor (EGF) VIII
(Mfge8). However, the deﬁciency of Mfge8 is deleterious only in
C57BL/6J129Svbutnot inC57BL/6Jmice (Kranichetal., 2008, 2010),
suggesting the existence of additional factors involved in prion
clearance (Aguzzi et al., 2013a). Developmental endothelial locuse1
(Del-1) was originally found as an endothelial cellederived extra-
cellularmatrix protein structurally containing 3 EGF-like repeats and
2 discoidin I-like domains. As a structural homolog of Mfge8, Del-1
can also bridge apoptotic cells and phagocytes to facilitate uptake
and removalof apoptotic cells (Hanayamaet al., 2004a).Del-1has also
appeared as an anti-inﬂammatory molecule (Choi et al., 2008, 2015).
In this study, we aimed to investigatewhether the phagocytosis-
promoting and anti-inﬂammatory functions of Del-1 may have an
impact on prion pathogenesis and to determine whether Del-1
complements Mfge8 in prion clearance in mice with a C57BL/6J
genetic background. We observed that Del-1-/- mice displayed
disease progression and lesion patterns similar to those of their
heterozygous (Del-1þ/-) and wild-type (Del-1þ/þ) littermates.
Importantly, PrPSc deposition was not altered by Del-1 deﬁciency,
suggesting that Del-1 is not involved in prion clearance in vivo.
Furthermore, Del-1 deﬁciency did not overtly affect prion-induced
neuroinﬂammation. On the basis of these observations, we
conclude with a high degree of conﬁdence that Del-1 is not a major
determinant of prion clearance and does not impact prion patho-
genesis in any measurable way. Del-1 does not complement Mfge8
in prion clearance in mice with a C57BL/6J genetic background.
2. Material and methods
2.1. Animals and ethical statement
Del-1-/- mice with a C57BL/6J genetic background (Choi et al.,
2008) were backcrossed to C57BL/6J mice to obtain Del-1þ/-
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offspring, which were then intercrossed to generate Del-1þ/þ (wild
type), Del-1þ/- and Del-1-/- mice for experiments described here.
Mfge8-/-/Del-1-/- double knockoutmicewere generated by breeding
Del-1-/- mice to Mfge8-/- mice (Hanayama et al., 2004b; Kranich
et al., 2010).
All animal experiments were carried out in strict accordance
with the rules and regulations for the Protection of Animal Rights
(Tierschutzgesetz and Tierschutzverordnung) of the Swiss Bunde-
samt für Lebensmittelsicherheit und Veterinärwesen and were
preemptively approved by the Animal Welfare Committee of the
Canton of Zürich (permit # 41/2012).
2.2. Prion inoculation
Mice at the age of 6e8 weeks were intracerebrally (i.c.) inocu-
latedwith 30 mL of brain homogenate diluted in phosphate buffered
saline with 5% bovine serum albumin and containing 3  105 LD50
units of the Rocky Mountain Laboratories scrapie strain (passage 6,
thus called RML6). Mice were monitored and actions were taken to
minimize animal suffering and distress according to details
described previously (Zhu et al., 2015b).
2.3. Quantitative real-time polymerase chain reaction
Quantitative real-time polymerase chain reaction (qRT-PCR) was
performed using the SYBRGreen PCRMasterMix (Roche) on a ViiA7
Real-Time PCR system (Applied Biosystems) as described previously
(Zhu et al., 2015a). Expression levels were normalized using glyc-
eraldehyde-3-phosphate dehydrogenase.
2.4. Immunohistochemistry
Immunohistochemical staining was performed as described
previously (Zhu et al., 2015a). Anti-PrP SAF-84 (1:200, SPI Bio,
A03208), anti-GFAP antibody (1:300; DAKO, Carpinteria, CA, USA),
and anti-Iba1 antibody (1:1000; Wako Chemicals GmbH, Germany)
were used to stain PrPSc, astrocytes, and microglia, respectively.
2.5. Western blot analysis
Proteins were loaded and separated on a 12% Bis-Tris poly-
acrylamide gel (NuPAGE, Invitrogen) and processed as described
previously (Zhu et al., 2015a). Primary antibodies anti-PrP antibody
POM1 (400 ng mL1), anti-NeuN clone EPR12763 (1:3000, Abcam,
ab177487), anti-synaptophysin clone 2/synaptophysin (1:10,000,
BD Biosciences, 611880), anti-synapsin I (1:2000, Millipore, AG,
USA, AB1543), anti-Iba1 antibody (1:1000; Wako Chemicals GmbH,
Germany, 019e19,741), anti-GFAP antibody (D1F4Q) XP Rabbit
mAb (1:3000; Cell Signaling Technology, 12,389), anti-Mfge8 anti-
body (1:1000; R&D Systems, AF2805), anti-actin antibody
(1:10,000, Millipore), and secondary antibody horseradish
peroxidaseeconjugated goat anti-mouse IgG (1:10,000, Jackson
ImmunoResearch, 115-035-003), goat anti-rabbit IgG (1:10,000,
Jackson ImmunoResearch, 111-035-045), and donkey anti-goat
IgG(1:10,000, Jackson ImmunoResearch, 705-035-147) were used.
For proteinase K (PK) digestion, samples were adjusted to 20 mg
protein in 20 mL and digested with 25 mg mL1 proteinase K for
30 minutes at 37 C.
2.6. Real-time quaking-induced conversion assay
Real-time quaking-induced conversion assay (RT-QuIC) assays of
prion-infected mouse brain homogenates were performed as pre-
viously described (Frontzek et al., 2016).
3. Results
3.1. Del-1 deﬁciency does not affect prion progression and lesion
pattern
Del-1 is highly expressed in mouse brains and mainly expressed
by neurons (Supplemental Figs. 1e5). Del-1 deﬁciency did not
change the transcription of Prnp and protein levels of the cellular
prion protein in brains (Fig. 1A and B), which are major de-
terminants of susceptibility to prion diseases. To determine the role
of Del-1 in prion diseases, we i.c. inoculated RML6 prions (a prion
strain derived from the Rocky Mountain Laboratory, passage 6) into
Del-1þ/þ, Del-1þ/-, and Del-1-/- littermates. We observed that Del-
1þ/þ, Del-1þ/-, and Del-1-/- mice succumbed to prion disease at a
similar rate [median survival: 186 dpi for female Del-1þ/þmice (n¼
6), 191.5 dpi for female Del-1þ/-(n ¼ 16), and 193.5 dpi for female
Del-1-/- mice (n ¼ 8), p ¼ 0.26; median survival 196.5 dpi for male
Del-1þ/þ mice(n ¼ 14), 195 dpi for male Del-1þ/-(n ¼ 19), and 197
dpi for male Del-1-/- mice (n ¼ 11), p ¼ 0.87] (Fig. 1C). These results
indicate that Del-1 deﬁciency does not signiﬁcantly affect prion
progression.
To determine whether Del-1 and Mfge8 work redundantly in
prion clearance, we bred Del-1-/- mice and Mfge8-/- mice to obtain
Mfge8-/-/Del-1-/- double knockout mice with a C57BL/6J genetic
background and i.c. inoculated RML6 prions. Again, we observed a
similar prion progression in Mfge8-/-/Del-1-/- double knockout and
wild-type (Mfge8þ/þ/Del-1þ/þ) littermates (median survival: 182.5
dpi for female Mfge8þ/þ/Del-1þ/þmice [n ¼ 4], 181.5 dpi for female
Mfge8-/-/Del-1-/- mice [n ¼ 4], p ¼ 0.72) (Supplemental Fig. 6),
suggesting that neither Del-1 nor Mfge8 is an important determi-
nant of prion pathogenesis in mice within the C57BL/6J genetic
background.
We then analyzed the histology of brain sections prepared from
prion-infected terminally sick Del-1þ/þ, Del-1þ/-, and Del-1-/- mice.
The typical histological features of prion disease, including spon-
giform vacuolation, were observed in all mice with different ge-
notypes (Fig. 1D). Lesion pattern analysis failed to ﬁnd any
qualitative differences between the 3 groups (Fig. 1D). These results
indicate that Del-1 deﬁciency does not affect prion-induced lesion
pattern in mouse brains. We then performed Western blots for
neuronal markers (NeuN, synaptophysin, and synapsin I) to assess
whether Del-1 deﬁciency affects prion-induced neuronal death; we
failed to observe obvious differences between Del-1þ/þ, Del-1þ/-,
and Del-1-/- mouse brains (Fig. 1E, full images of the cropped
Western blots are shown in Supplementary Fig. 7). Therefore, Del-1
deﬁciency does not alter prion-induced neuronal death.
3.2. Del-1 deﬁciency does not alter PrPSc accumulation
We next sought to determine whether Del-1 is involved in prion
clearance in mouse brains. We performed PrPSc staining on brain
sections prepared from prion-infected terminally sick Del-1þ/þ,
Del-1þ/-, and Del-1-/- mice. However, we observed similar PrPSc
deposition level in all 3 groups (Fig. 2A). We next carried out
Western blot to detect proteinase Keresistant PrPSc in brains of
prion-infected terminally sick Del-1þ/þ, Del-1þ/-, and Del-1-/- mice.
Again, we found similar levels of PrPSc in mouse brains of the 3
genotypes (Fig. 2B). Furthermore, we assessed the seeding activity
in brain homogenates of prion-infected terminally sick Del-1þ/þ,
Del-1þ/-, and Del-1-/- mice by RT-QuIC. We detected a similar prion
50% seeding dose in all 3 groups (Fig. 2C). These results suggest that
Del-1 does not contribute to prion clearance and PrPSc accumula-
tion in mouse brains.
To test the possibility that Del-1 deﬁciency could upregulate
Mfge8 expression through a compensatory mechanism, thereby
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Fig. 1. (A and B) Prnp qRT-PCR (A) and PrPC Western blot (B left; densitometric quantiﬁcation of the Western blot in B right) in Del-1þ/þ (WT), Del-1þ/-, and Del-1-/- mouse brains. No
signiﬁcant difference in PrnpmRNA and PrPC proteinwas observed between Del-1þ/þ (WT), Del-1þ/-, and Del-1-/- mouse brains. Relative expressionwas represented as percentage of
average values in Del-1þ/þ controlmice. (C) Survival curve of Del-1þ/þ (WT), Del-1þ/-, and Del-1-/- littermates intracerebrally inoculatedwith RML6. Therewas no signiﬁcant difference
between 3 groups in both genders (n¼ 6e19, n.s p> 0.05). (D) Representative histology of terminally sick mouse brains from Del-1þ/þ (WT), Del-1þ/-, and Del-1-/- littermates stained
with hematoxylin and eosin (H&E). There was no obvious difference between the 3 groups with respect to vacuolation or lesion pattern in the cortex, hippocampus, and cerebellum,
scale bars: 200 mm. (E) Left: Western blot for NeuN, synaptophysin, and synapsin I in prion-infected Del-1þ/þ (WT), Del-1þ/-, and Del-1-/- mouse brains. Right: densitometric quan-
tiﬁcation of the NeuN, synaptophysin, and synapsin I Western blots. n¼ 3 for each genotype. The relative signal intensity was represented as percentage of average values in Del-1þ/þ
control mice. Therewas no signiﬁcant difference between 3 groups in both genders (n¼ 3, n.s p> 0.05). Abbreviations: Del-1, developmental endothelial locuse1; PrPC, cellular prion
protein; qRT-PCR, quantitative real-time polymerase chain reaction; RML6, Rocky Mountain Laboratories scrapie strain, passage 6; WT, wild type.
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blunting the acceleration of prion progression in Del-1-/- mice, we
assessed the expression of Mfge8 in Del-1þ/þ, Del-1þ/-, and Del-1-/-
mouse brains. Both qRT-PCR and Western blot failed to detect
obvious changes in Mfge8 mRNA and protein levels in Del-1-/-
mouse brains (Fig. 2D and E, full image of the croppedWestern blots
is shown in Supplementary Fig. 7), suggesting that the unchanged
prion pathogenesis in Del-1-/- mice is not due to a compensatory
effect of its homolog Mfge8.
Fig. 2. (A) Left: Representative histology of terminally sick mouse brains from Del-1þ/þ (WT), Del-1þ/-, and Del-1-/- littermates stained for SAF84. There was no obvious difference
between the 3 groups in PrPSc deposition in the cortex, hippocampus, and cerebellum, scale bars: 200 mm. Right: quantiﬁcation of the SAF84 staining in the cortex, cerebellum, and
hippocampus of Del-1þ/þ (WT), Del-1þ/-, and Del-1-/- littermates (n ¼ 5, n.s p > 0.05). Relative signal intensity was represented as percentage of average values in Del-1þ/þ control
mice. (B) Left: Western blot for proteinase Keresistant PrPSc in terminally sick mouse brains. Right: densitometric quantiﬁcation of the Western blot showed no signiﬁcant dif-
ference between Del-1þ/þ (WT), Del-1þ/-, and Del-1-/- littermates (n ¼ 3, n.s p > 0.05). (C) RT-QuIC assay of terminally sick mouse brains from Del-1þ/þ (WT), Del-1þ/-, and Del-1-/-
littermates showed similar level of 50% prion seeding dose in these 3 groups (n ¼ 4, n.s p > 0.05). (D and E) Mfge8 qRT-PCR (D) and Mfge8 Western blot (E left; densitometric
quantiﬁcation of the Western blot in E right) in Del-1þ/þ (WT), Del-1þ/-, and Del-1-/- mouse brains. No signiﬁcant difference of Mfge8 mRNA and Mfge8 protein was observed
between Del-1þ/þ (WT), Del-1þ/-, and Del-1-/- mouse brains. Abbreviations: Del-1, developmental endothelial locuse1; NBH, noninfectious brain homogenates; Mfge8, milk-fat
globule EGF factor VIII; qRT-PCR, quantitative real-time polymerase chain reaction; RT-QuIC, real-time quaking-induced conversion assay; WT, wild type.
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Fig. 3. (A and B) Representative immunohistochemical staining for Iba1 (A) and GFAP (B) in the cortex, hippocampus, and cerebellum of terminally sick mouse brains from Del-1þ/þ
(WT), Del-1þ/-, and Del-1-/- littermates, scale bars: 100 mm. (C) Left: Western blot for Iba1 in terminally sick mouse brains. Right: densitometric quantiﬁcation of the Western blot
revealed no signiﬁcant difference in Iba1 levels between Del-1þ/þ (WT), Del-1þ/-, and Del-1-/- littermates (n ¼ 3, n.s p > 0.05). (D) Left: Western blot for GFAP in terminally sick
mouse brains. Right: densitometric quantiﬁcation of the Western blot showed no signiﬁcant difference of GFAP levels between Del-1þ/þ (WT), Del-1þ/-, and Del-1-/- littermates (n ¼
3, n.s p > 0.05). (E) qRT-PCR of cytokines tumor necrosis factor a, interleukin 6, and interleukin-1b expression revealed similar expression levels of these cytokines in terminally sick
Del-1þ/þ (WT), Del-1þ/-, and Del-1-/- littermates (n ¼ 4, n.s p > 0.05). Abbreviations: Del-1, developmental endothelial locuse1; GFAP, glial ﬁbrillary acidic protein; qRT-PCR,
quantitative real-time polymerase chain reaction; WT, wild type.
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3.3. Del-1 deﬁciency does not affect prion-induced
neuroinﬂammation
To determine whether Del-1 also plays an anti-inﬂammatory
effect in prion pathogenesis, we analyzed microglial activation
and astrogliosis in prion-infected terminally sick Del-1þ/þ, Del-1þ/-,
and Del-1-/- mice. Histology failed to reveal overt differences in Iba1
(microglial marker) and glial ﬁbrillary acidic protein (GFAP, astro-
cytic marker) immunoreactivity between Del-1þ/þ, Del-1þ/-, and
Del-1-/- mice (Fig. 3A and B). We then performed Western blots to
detect Iba1 and GFAP protein in prion-infected terminally sick Del-
1þ/þ, Del-1þ/-, and Del-1-/- mouse brains. Again, we observed
similar levels of Iba1 and GFAP in all 3 groups (Fig. 3C and D, full
images of the cropped Western blots are shown in Supplementary
Fig. 7). These results suggest that, in contrast to other models of
neurological disease such as EAE, Del-1 deﬁciency does not overtly
affect prion-induced microglial activation and astrogliosis.
We also performed cytokine proﬁling using qRT-PCR to assess
the expression of proinﬂammatory cytokines including tumor ne-
crosis factor a, interleukin-1b, and interleukin 6 in prion-infected
terminally sick Del-1þ/þ, Del-1þ/-, and Del-1-/- mouse brains. This
experiment did not detect obvious differences in cytokine expres-
sion between the 3 groups (Fig. 3E), suggesting that Del-1 deﬁ-
ciency fails to alter prion-induced cytokine expression.
4. Discussion
Neuroinﬂammation, characterized by astrogliosis and microglial
activation, is considered a hallmark of various neurodegenerative
conditions including Alzheimer’s disease and prion diseases
(Aguzzi et al., 2013a). The molecular mechanisms by which
microglia contribute to the pathogenesis of neurodegenerative
conditions are subjected to extensive investigations. In this study,
we aimed to study whether Del-1 plays phagocytosis-promoting
and/or anti-inﬂammation functions in prion diseases. In partic-
ular, we sought to determine whether Del-1 complements Mfge8 in
prion clearance in mice with a C57BL/6J genetic background, in
which Mfge8 deﬁciency does not inﬂuence prion pathogenesis. We
observed that Del-1-/- mice experienced a similar incubation time
compared to Del-1þ/- and wild-type littermates, suggesting that
Del-1 deﬁciency does not affect prion disease progression. More
importantly, the PrPSc level and prion seeding activity were not
detectably affected byDel-1 deﬁciency, indicating that Del-1 is not a
major contributor to prion clearance. Moreover, prion-induced
astrocytosis and microglial activation were not altered in Del-1-/-
mouse brains, suggesting that Del-1 deﬁciency does not overtly
affect prion-induced neuroinﬂammation. Therefore, our study
revealed that Del-1 is not a major determinant of prion pathogen-
esis and does not complement Mfge8 in prion clearance in mice
with the C57BL/6J genetic background. Further studies are required
to identify molecular mechanisms underlying microglial uptake
and clearance of prions.
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